Biohaven partners with Ono in $100m IgG degrader deal
Biohaven partners with Ono in $100m IgG degrader deal
Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.